Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Non Operating Income (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Non Operating Income for 7 consecutive years, with $25.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income rose 2.59% year-over-year to $25.1 million, compared with a TTM value of $24.3 million through Dec 2025, down 30.42%, and an annual FY2025 reading of $24.3 million, up 2.3% over the prior year.
  • Non Operating Income was $25.1 million for Q4 2025 at Keros Therapeutics, up from -$14.2 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $25.1 million in Q4 2025 and bottomed at -$14.2 million in Q3 2025.
  • Average Non Operating Income over 5 years is $3.4 million, with a median of $2.0 million recorded in 2022.
  • The sharpest move saw Non Operating Income soared 13522.5% in 2024, then tumbled 15296.74% in 2025.
  • Year by year, Non Operating Income stood at -$100000.0 in 2021, then plummeted by 8382.0% to -$8.5 million in 2022, then soared by 173.24% to $6.2 million in 2023, then surged by 294.48% to $24.5 million in 2024, then rose by 2.59% to $25.1 million in 2025.
  • Business Quant data shows Non Operating Income for KROS at $25.1 million in Q4 2025, -$14.2 million in Q3 2025, and $6.9 million in Q2 2025.